Jundishapur Journal of Health Sciences

Published by: Kowsar

Analysis of Cardiovascular Diseases Costs and Their Effective Factors in Tabriz Hospitalized Patients, 2015

Ali Imani 1 , Farid Gharibi 2 , * , Ozra Dadashi 3 , Mahdiyeh Najafi 3 and Seyed Mahdi Mirbagheri 4
Authors Information
1 Department of Health Services Management, Iranian Center of Excellence in Health Management (IceHM), School of Health Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, IR Iran
2 Department of Health Services Management, Students’ Research Committee, Tabriz University of Medical Sciences, Tabriz, IR Iran
3 Department of Health Services Management, School of Health Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, IR Iran
4 Department of Pharmacology, Islamic Azad University, Ahar Branch, Ahar, IR Iran
Article information
  • Jundishapur Journal of Health Sciences: April 01, 2016, 8 (2); e32503
  • Published Online: January 9, 2016
  • Article Type: Research Article
  • Received: August 17, 2015
  • Revised: October 31, 2015
  • Accepted: November 3, 2015
  • DOI: 10.17795/jjhs-32503

To Cite: Imani A, Gharibi F, Dadashi O, Najafi M, Mirbagheri S M. et al. Analysis of Cardiovascular Diseases Costs and Their Effective Factors in Tabriz Hospitalized Patients, 2015, Jundishapur J Health Sci. 2016 ;8(2):e32503. doi: 10.17795/jjhs-32503.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Rosen VM, Taylor DC, Parekh H, Pandya A, Thompson D, Kuznik A, et al. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics. 2010; 28(1): 47-60[DOI][PubMed]
  • 2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating G. Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360(9343): 1347-60[DOI][PubMed]
  • 3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404): 1419[DOI][PubMed]
  • 4. Mason H, Shoaibi A, Ghandour R, O'Flaherty M, Capewell S, Khatib R, et al. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries. PLoS One. 2014; 9(1)[DOI][PubMed]
  • 5. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol. 2010; 35(2): 72-115[DOI][PubMed]
  • 6. Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri Kashani A. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord. 2007; 7: 32[DOI][PubMed]
  • 7. Rastegarpanah M, Malekzadeh F, Thomas GN, Mohagheghi A, Cheng KK, Marshall T. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"? Arch Iran Med. 2008; 11(3): 306-13[PubMed]
  • 8. Namazi MH, Mohagheghi A, Ostovaneh MR. Prevention of cardiovascular diseases in developing countries. Arch Iran Med. 2012; 15(9): 528-30[PubMed]
  • 9. Zheng H, Ehrlich F, Amin J. Economic evaluation of the direct healthcare cost savings resulting from the use of walking interventions to prevent coronary heart disease in Australia. Int J Health Care Finance Econ. 2010; 10(2): 187-201[DOI][PubMed]
  • 10. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust. 2008; 188(1): 36-40[PubMed]
  • 11. Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health. 2012; 12: 398[DOI][PubMed]
  • 12. McMurray JJV, Pfeffer MA. Heart failure. The Lancet. 2005; 365(9474): 1877-89[DOI]
  • 13. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002; 4(3): 361-71[PubMed]
  • 14. Seo HY, Yoon SJ, Kim EJ, Oh IH, Lee YH, Kim YA. The economic burden of rheumatic heart disease in South Korea. Rheumatol Int. 2013; 33(6): 1505-10[DOI][PubMed]
  • 15. Imani A, Ahmadipoor S, Jannati A, Gholipour K, Ghoddoosi-Nejad J. Analysis and estimation of the direct and indirect costs of breast cancer in women attending Shahid Ghazi clinic, Tabriz, 2013 [In Persian]. Depict Health. 2014; 5(3): 13-9
  • 16. Mourad G, Alwin J, Stromberg A, Jaarsma T. Societal costs of non-cardiac chest pain compared with ischemic heart disease--a longitudinal study. BMC Health Serv Res. 2013; 13: 403[DOI][PubMed]
  • 17. Hajizadeh E, Asghari M. Statistical methods and analyses in health biosciences [In Persian]. 2010; : 397-422
  • 18. Yaghmale F. Content validity and its estimation. J Med Educ. 2003; 3(1): 25-7
  • 19. Goss JR. 2008;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments